PolyMedix, UMass get Phase 2 STTR grant
Sponsored by the US Army Research Office, the grant will allow PolyMedix to conduct further testing on antimicrobial compounds which PolyMedix identified under the initial Phase 1 contract.
China-based clinical-stage biotechnology company BoomRay Pharmaceuticals and Novartis Pharma have signed an exclusive worldwide licence deal for an undisclosed preclinical radioligand therapy (RLT) asset in a deal worth up to $900m.